Yale Daily News

Yale Daily news: Yale’s Yale School of Medicine, which has seen its enrollment drop from more than 100,000 students in 2011 to about 35,000 in 2016, is looking for a new CEO.

The university’s board of trustees announced Tuesday that it is seeking a new leader for the school, which is in the midst of a $10 billion restructuring.

The board is expected to make a final decision in the coming weeks.

Yale is facing a number of challenges, including a growing number of new students and faculty.

The school has seen enrollment drop to around 40,000 this past year from nearly 100,064 in 2011.

“We are deeply disappointed in the board’s decision to terminate its Board of Trustees’ engagement with us on this matter,” said Yale President Christopher A. Dolan in a statement.

“It is important to recognize that this is an unprecedented and disruptive move.

While we respect the Board’s decision, we are confident that the Board will work with us to create a new leadership team that is focused on addressing these challenges and the continued success of our student health care team,” he said.

Dameron said the board has invited other interested parties to participate in the search process, including the Harvard Business School, New York University, and the New England College of Physicians and Surgeons.

The trustees have not set a date for a hiring of a new dean.

Yale said the university’s new chancellor will be appointed in July.

Dallaire, who was Yale’s first female dean, took over in December.

In January, Dallainces administration announced it was ending the school’s partnership with Pfizer, the maker of the popular Eli Lilly & Co. drug Vioxx, after the drugmaker’s marketing company, Amgen, filed a lawsuit accusing the university of violating antitrust laws by not paying for its Viox product.

Dillaire, a former president of the National College of Surgeons, has been critical of Pfizer’s business practices, particularly its use of its own marketing platform and by the company’s employees.

A spokesman for the university said the company will continue to cooperate with the board in its investigation into the matter.

“I am disappointed that the board is terminating the engagement of the Board of Regents,” Dallares spokesperson Michael T. Stegall said in a written statement.

The move comes as the board tries to make the university more attractive to potential donors.

Yale’s enrollment fell from nearly 1.1 million in 2011, when Dallays administration was still in charge, to less than 100 the following year, according to the university.

Dalee Hall, a spokeswoman for the University of Texas System, which also runs the Yale campus, said in an emailed statement that “Yale remains a leader in health care research, the best in the nation and one of the best performing public research universities in the country.”

Dallaires administration said the end of the agreement was “an important milestone for our mission” to improve the academic reputation of Yale.